Bsense pruritus program

Bsense Bio Therapeutics is developing a small molecule dual modulator for the treatment of pruritus (itch). The drug candidate targets sensory neuron hyperexcitability by simultaneously inhibiting the Transient Receptor Potential Vanilloid 1 (TRPV1) channel and activating the Potassium Voltage-Gated Channel Subfamily Q Member 2/3 (Kv7.2/3). TRPV1 is a well-known mediator of pain and itch, while Kv7.2/3 channels play a critical role in stabilizing the resting membrane potential of neurons. By combining these two mechanisms into a single molecule, the therapy aims to provide a more effective reduction in the neuronal firing associated with chronic itch conditions. The program is currently in preclinical development.